Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts give Janux an average recommendation of Moderate Buy from 14 firms (10 buys, 3 holds, 1 sell), with an average one-year price target of $53.09.
• Janux reported quarterly EPS of ($0.51), beating consensus ($0.65), and revenue of $7.88M versus $0.08M expected, but the company remains unprofitable with analysts forecasting about ($1.38) EPS for the current fiscal year.
• Shares trade around $15.19 (12‑month range $12.12–$35.34) with a market cap near $924M, and Janux is a clinical-stage biotech developing intratumoral TLR agonists including JTX-8064 and JTX-4014.

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $53.0909.

JANX has been the topic of a number of recent research reports. Clear Str cut shares of Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 20th. Cantor Fitzgerald dropped their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Guggenheim dropped their price target on shares of Janux Therapeutics from $72.00 to $68.00 and set a "buy" rating on the stock in a research note on Friday, February 27th. Wall Street Zen upgraded shares of Janux Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, April 5th. Finally, Piper Sandler dropped their price target on shares of Janux Therapeutics from $42.00 to $30.00 and set an "overweight" rating on the stock in a research note on Friday, January 16th.

Janux Therapeutics Stock Up 1.0%

Janux Therapeutics stock opened at $15.19 on Friday. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34. The firm has a 50 day moving average price of $13.90 and a 200-day moving average price of $18.46. The company has a market capitalization of $924.01 million, a P/E ratio of -8.30 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to analysts' expectations of $0.08 million. Equities analysts expect that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

Institutional investors have recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Janux Therapeutics in the 4th quarter worth $34,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Janux Therapeutics in the 4th quarter worth $51,000. Osaic Holdings Inc. increased its holdings in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after buying an additional 3,037 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after buying an additional 2,502 shares during the last quarter. Finally, Winthrop Capital Management LLC bought a new position in shares of Janux Therapeutics in the 3rd quarter worth $106,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.